|
The Center
for Interdisciplinary Research on Antimicrobial
Resistance (CIRAR) hosted a closed forum for
industry representatives in the field of antimicrobial
therapeutics and diagnostics. This half-day forum, which
included over 40 attendees, provided
opportunity to discuss perspectives of the gaps in research
related to antimicrobial resistance and potential areas for
collaboration among industry and academia. The
forum also served as a venue to network, discuss common problems,
interests, challenges, and, ultimately, lead to potential research
projects and collaborative work.
Specific Aims of the CIRAR Forum for
Industry Representatives in the Field of Antimicrobial
Therapeutics and Diagnostics were:
|
1. |
To bring industry
and CIRAR together to discuss the gaps in research related to
antimicrobial resistance and potential areas for
collaboration. |
|
2. |
To identify
barriers to the development of effective antimicrobial agents
active against drug resistant pathogens and ways to overcome
these challenges. |
|
3. |
To discuss the
impact of multidrug resistance from the perspective of
industry, academic health centers, and the community at large. |
|
4. |
To analyze the
impact of rapid detection of antimicrobial resistance on
patient management and therapeutic outcomes. |
|
5. |
To develop ideas
for potential research projects and interface between industry
and CIRAR. |
|
Panel I
- Diagnostics Industry Panel
Dr. Elaine Larson,
CIRAR Director, prefaced the forum with a presentation of the
background and history of CIRAR.
Download her presentation.
|
 |
CIRAR Executive
Committee Member, Dr. Phyllis Della-Latta, Director of
Clinical Microbiology Service (left), offers presentation on
"Bridging Academic and Industrial Gaps."
Download the presentation. |
| Dr. Phyllis
Della-Latta leads the panel of industry experts on diagnostics
(right) in a stimulating discussion of barriers and opportunities
in interdisciplinary work between industry and academia in the
field of antimicrobial resistance. |
 |
Diagnostics Panel members
included Mary Motyl (Merck & Co, Inc), Vivian Jonas-Taggart
(Gen-Probe), Stephen Day (Third Wave Molecular Diagnostics), Nadine
Sullivan (TREK Dx), Christine Borjesson (AB Biodisk), Jane Hata (BioMerieux,
Inc.), John Meduri (Becton Dickinson), Barry Kreiswirth (International
Center for Public Health), David Perlin (International Center for
Public Health), and Alan Evangelista (Ortho-McNeil Pharmaceutical,
Inc.).
Panel II - Therapeutics
Industry Panel
Christine Kubin, PharmD,
BCPS, Clinical Pharmacist, Infectious Diseases at NewYork-Presbyterian
Hospital, prefaced and led the Therapeutics Industry Panel.
Download her presentation.
|
|
Steven J. Projan,
Ph.D., Vice President, Biological Technologies, Wyeth
Research, and member of the Therapeutics Industry Panel
(left), speaks on the barriers to antibacterial drug development.
Download the presentation. |
| Seth Hetherington,
Vice President of Clinical Affairs and Chief Medical Officer of
Inhibitex, Inc., and member of the Therapeutics Industry Panel
(right), gives presentation on "Antibody Approaches to Infectious
Diseases: Clinical Programs at Inhibitex."
Download the presentation. |
|
|
|
Charles Knirsch,
Senior Medical Director, Anti-Infectives, Pfizer and
member of the Therapeutics Industry Panel (left), presents on
"Opportunities and Obstacles in Academic-Industry Collaborations."
Download the presentation. |
|
CIRAR Expert Liaison,
Dr. Scott Hammer (right), summarizes the key points of the
forum, focusing on identified barriers to and opportunities
available through interdisciplinary collaboration between industry
and academia. |
 |
INDUSTRY
FORUM - PANEL TOPICS
Diagnostics Panel:
What do you perceive as barriers to
meeting the goal of developing and implementing real-time detection of
resistant & virulent pathogens?
What are the major clinical, financial
and societal challenges that could be addressed by interdisciplinary
outcome studies?
How can CIRAR assist industry in
addressing regulatory barriers that hinder the implementation of new
technologies?
Since research and development
resources are limited, what are innovative ways for academia and
industry to work together in research?
How can CIRAR and industry partner to
meet our shared objectives?
Therapeutics Panel:
The antibiotics pipeline and challenges
from industry’s perspective.
Novel approaches to
treatment/colonization.
Opportunities for academia/industry and
what are the barriers.
|
